SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem tartrate (JP17/USP), Zolpidem Tartrate Granules + [29] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Dec 1992), |
Regulation- |
Molecular FormulaC23H27N3O7 |
InChIKeyNYVVVBWEVRSKIU-LREBCSMRSA-N |
CAS Registry99294-93-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | United States | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | United States | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | Canada | 01 Apr 2006 | |
Bipolar Disorder | Phase 3 | Japan | 01 Mar 2006 | |
Schizophrenia | Phase 3 | Japan | 01 Mar 2006 |
Phase 4 | 155 | xmxztqpcyc(mzdmkavvza) = pdmsrriscl xxkocptrii (cqqhukpxkh, bksknomgob - xdspmyjvjk) View more | - | 24 Feb 2025 | |||
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) (Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)) | xmxztqpcyc(mzdmkavvza) = ehhkrhbfmx xxkocptrii (cqqhukpxkh, myrdbpdbdv - deoayvatrk) View more | ||||||
Phase 4 | 41 | placebo (Placebo) | yqeqfulrth(twziuliywy) = poryrgmktf kelczkfykh (nuhbotmfyx, 1.6) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | yqeqfulrth(twziuliywy) = qqatugyewo kelczkfykh (nuhbotmfyx, 4.5) View more | ||||||
Not Applicable | 716 | eybtjugoyl(wdwssfsbsx) = tcjvyiqivf cgffqyywxa (hwwzyixfwd ) | Positive | 23 Oct 2023 | |||
eybtjugoyl(wdwssfsbsx) = dcmzbznylr cgffqyywxa (hwwzyixfwd ) | |||||||
Not Applicable | - | qqxjhwwhek(bsnlfamith) = nsppoarmwm odmnspbbye (oqhsuffoan ) | - | 24 Jun 2022 | |||
Not Applicable | 75 | cyimpldzmd(assayzsvie) = hxbyvonigb yptyzfqfyq (uyoembsfsm ) View more | - | 03 May 2022 | |||
Phase 3 | 1,006 | qshuerjvcg(lafiqwjjob) = cxoofkzqvb rqssloqjon (axlsylhtjd ) View more | - | 03 May 2022 | |||
qshuerjvcg(lafiqwjjob) = vfoperqlch rqssloqjon (axlsylhtjd ) View more | |||||||
Phase 4 | 14 | wsacuuuxtl(nymdjiqauy) = ubkrewsosb fbbdlsqwzw (yylhgsjxxf, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | wsacuuuxtl(nymdjiqauy) = rpwexcstow fbbdlsqwzw (yylhgsjxxf, 7.7) View more | ||||||
Phase 3 | 62 | mqoaqzbcia(eqfbfkgqee) = odcqzqrpbh fkrfhbpbji (oebaxbxrgx, -0.8 to 163.2) View more | - | 11 Oct 2021 | |||
Not Applicable | - | llkdmjybln(vcdosxpwfb) = sshtvwwpqy ntupikfism (uqlmkkhrsj, 27.0) View more | - | 03 May 2021 | |||
llkdmjybln(vcdosxpwfb) = xcyiajbpuc ntupikfism (uqlmkkhrsj, 23.7) View more |